Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Schizophrenia
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Schizophrenia
    TopAbstracts in Schizophrenia 10/29/2009 - (DGNews)
    Use of Antipsychotic Medications by Children and Adolescents Associated With Significant Weight Gain - (DGNews)
    TopAbstracts in Schizophrenia 10/15/2009 - (DGNews)
    TopAbstracts in Schizophrenia 10/01/2009 - (DGNews)
    Patients Receiving Antipsychotic Treatment at High Risk of Cardiovascular Disease: Presented at ECNP - (DGDispatch)

    News archive

     Recent webcasts/CME - Schizophrenia

    Webcasts/CME archive

     Recent cases - Schizophrenia
      Graves' Disease Presenting as Paranoid Schizophrenia in a Nigerian Woman: A Case Report
      Schizophrenia-Like Psychosis Following Left Putamen Infarct: A Case Report
      Localisation Using Mini C-Arm Fluoroscopy of Needles Ingested by a Woman with Schizophrenia: A Case Report
      Schizophrenia Spectrum Disorders in a Nigerian Family: 4 Case Reports
      Massive Pulmonary Emboli Associated with Olanzapine

      Cases archive
        




      my personal edition > schizophrenia > news
      divider

        E-Mail this DGNews to a colleague

      DGNews


      FazaClo (Clozapine) Orally Disintegrating Tablets Available in US for Patients Unresponsive to Standard Schizophrenia Treatments

      PARSIPPANY, NJ -- July 21, 2004 -- Alamo Pharmaceuticals introduced itself and its unique new product FazaClo(TM) (clozapine, USP) Orally Disintegrating Tablets to the nation's psychiatrists today.

      Expected to bring patients new convenience and discreet dosing options, FazaClo is the patented orally disintegrating form of a drug reserved for the management of severely ill patients with schizophrenia who fail to respond adequately to standard drug treatment for schizophrenia.

      "We're confident that psychiatrists and their patients will welcome the new freedom that FazaClo orally disintegrating tablets present. No longer will clozapine patients need to locate a beverage or otherwise draw attention to their need for medication," stated psychiatrist Neal R. Cutler, MD, founder, president and CEO of the California-based company. "FazaClo is particularly convenient for active, working patients getting on with their lives."

      A unique, mint flavored formulation using the proprietary OraSolv® technology licensed from CIMA LABS INC., FazaClo is Alamo Pharmaceuticals' first product to reach the market. Alamo Pharmaceuticals has several additional products in the late stages of clinical development. The company's research and development work is managed at Alamo Pharmaceuticals' Beverly Hills, California headquarters; an office for pharmaceutical operations and sales is located in Parsippany, New Jersey.

      Heading up the FazaClo launch efforts is executive vice president, Paul Duffy, who formerly managed Novartis Pharmaceuticals Corporation's successful Clozaril®(1) (clozapine) marketing and sales.

      "We've assembled an organization of experienced psychiatric sales specialists and systems consultants to enable Alamo Pharmaceuticals to provide psychiatrists and other mental health professionals with a complete array of support services from day one," commented Duffy. "From our state-of-the-art computerized patient registry to our highly responsive call center, we aim to take the lead when it comes to supporting FazaClo patient safety."

      Because of the risk of agranulocytosis and granulocytopenia associated with the use of clozapine, Alamo Pharmaceuticals has developed a monitoring system called the FazaClo™ Patient Registry. Prescribing physicians, dispensing pharmacists and FazaClo™ (clozapine, USP) patients must be registered in the FazaClo™ Patient Registry, which will compare patient information against the National Non-Rechallenge Masterfile and maintain a continuing record of WBC values and related information for all patients who receive FazaClo™ Orally Disintegrating Tablets.

      PRESCRIBING INFORMATION

      Please see full Prescribing Information, including BOXED WARNINGS regarding agranulocytosis, seizures, myocarditis, and other adverse cardiovascular and respiratory effects. Do not open tablet blister until immediately prior to use. Phenylketonurics: FazaClo Orally Disintegrating Tablets contain phenylalanine. FazaClo(TM) (clozapine, USP) Orally Disintegrating Tablets are bioequivalent to and may be substituted for Clozaril(R)(1) (clozapine) tablets on a milligram for milligram basis(2).

      (1) Clozaril(R) (clozapine) is a registered trademark of Novartis Pharmaceuticals Corporation

      (2) Data on file, Alamo Pharmaceuticals


      SOURCE: Alamo Pharmaceuticals



      E-Mail this DGNews to a colleague   To print, use this version






      All contents Copyright (c) 1995-2009 Doctor's Guide Publishing Limited. All rights reserved.



      The NTK initiative. Physicians helping physicians identify Need-To-Know science
         Feedback
      Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
      Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
      1
      2
      3
      4
      5
      6
      7
      Send